Ganciclovir: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
* Guanosine nucleoside analogue similar to acyclovir |
* Guanosine nucleoside analogue similar to acyclovir |
||
* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase |
* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase |
||
| + | * Major toxicity is cytopenias |
||
* Resistance in [[CMV]] |
* Resistance in [[CMV]] |
||
** Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form |
** Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form |
||
Revision as of 10:08, 24 October 2019
- Guanosine nucleoside analogue similar to acyclovir
- Inhibits all human herpesviruses by inhibiting DNA polymerase
- Major toxicity is cytopenias
- Resistance in CMV
- Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
- Can also develop through mutations in the target UL54 DNA polymerase
- Oral bioavailability 6-8%
- Indications: CMV after hematopoietic stem cell transplantation, CMV after solid organ transplantation, Congenital CMV, Cytomegalovirus, Herpesviridae, Macacine alphaherpesvirus 1, Post-transplant acute limbic encephalitis
